Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$25.95 - $36.95 $608,086 - $865,849
23,433 New
23,433 $653,000
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $170,222 - $224,290
6,914 Added 37.5%
25,353 $659,000
Q2 2022

Aug 09, 2022

BUY
$19.74 - $29.01 $363,985 - $534,915
18,439 New
18,439 $505,000
Q1 2022

May 11, 2022

SELL
$26.68 - $41.63 $286,649 - $447,272
-10,744 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$33.67 - $43.44 $18,484 - $23,848
-549 Reduced 4.86%
10,744 $431,000
Q3 2021

Nov 12, 2021

BUY
$30.65 - $35.68 $346,130 - $402,934
11,293 New
11,293 $369,000
Q1 2020

May 12, 2020

SELL
$20.69 - $37.79 $543,836 - $993,310
-26,285 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$32.75 - $41.43 $482,112 - $609,891
14,721 Added 127.3%
26,285 $904,000
Q3 2019

Nov 12, 2019

SELL
$33.73 - $46.27 $231,084 - $316,995
-6,851 Reduced 37.2%
11,564 $390,000
Q2 2019

Aug 06, 2019

BUY
$29.6 - $40.93 $261,397 - $361,452
8,831 Added 92.14%
18,415 $754,000
Q1 2019

May 15, 2019

BUY
$27.85 - $38.09 $5,959 - $8,151
214 Added 2.28%
9,584 $298,000
Q4 2018

Feb 12, 2019

BUY
$32.39 - $42.05 $303,494 - $394,008
9,370 New
9,370 $339,000
Q3 2018

Nov 13, 2018

SELL
$35.69 - $47.65 $1.19 Million - $1.59 Million
-33,270 Closed
0 $0
Q2 2018

Aug 09, 2018

SELL
$28.41 - $42.41 $614,508 - $917,328
-21,630 Reduced 39.4%
33,270 $1.23 Million
Q1 2018

May 11, 2018

SELL
$21.18 - $33.78 $910,740 - $1.45 Million
-43,000 Reduced 43.92%
54,900 $1.65 Million
Q4 2017

Feb 14, 2018

BUY
$19.29 - $24.83 $486,108 - $625,716
25,200 Added 34.66%
97,900 $2.15 Million
Q3 2017

Nov 20, 2017

BUY
$19.61 - $23.35 $1.43 Million - $1.7 Million
72,700
72,700 $1.67 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.09B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.